Cyy-272 is an orally active JNK inhibitor with IC50 values of 1.25 µM for JNK1, 1.07 µM for JNK2, and 1.24 µM for JNK3. Cyy-272 exerts anti-inflammatory effects by inhibiting JNK phosphorylation, thereby alleviating acute lung injury (ALI) induced by lipopolysaccharide (LPS, HY-D1056). Additionally, Cyy-272 significantly reduces inflammation in cardiomyocytes and cardiac tissue induced by high lipid concentrations, further mitigating cardiac hypertrophy, fibrosis, and apoptosis. Cyy-272 can be used in the study of obese cardiomyopathy[1].
Molecular Weight:
435.47
CAS Number:
[2644673-01-6]
Formula:
C23H23F2N7
Target:
Apoptosis,JNK
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
